预约演示
更新于：2025-08-12
Levocarnitine
左卡尼汀
更新于：2025-08-12
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C7H15NO3 |
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N |
CAS号541-15-1 |
关联
289
项与 左卡尼汀 相关的临床试验NCT07108777
Clinical Study to Evaluate the Possible Protective Effect of L-Carnitine Against Cisplatin-Induced Nephrotoxicity
NCT06564909
Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
NCT06960694
Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
100 项与 左卡尼汀 相关的临床结果
登录后查看更多信息
100 项与 左卡尼汀 相关的转化医学
登录后查看更多信息
100 项与 左卡尼汀 相关的专利（医药）
登录后查看更多信息
12,366
项与 左卡尼汀 相关的文献（医药）2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Improved insulin sensitivity and reproductive profile in overweight/obese PCOS patients undergoing integrative treatment with carnitines, L-arginine, L-cysteine and myo-inositol
Article
作者: Rusce, Maria Laura ; Spelta, Eleonora ; Battipaglia, Christian ; Genazzani, Alessandro D. ; Foschi, Martina ; Kostrzak, Anna ; Szeliga, Anna ; Meczekalski, Blazej ; Aio, Claudia ; Semprini, Elisa
OBJECTIVE:
To evaluate the effects of a combination of carnitines, L-arginine, L-cysteine and myo-inositol on metabolic and reproductive parameters in PCOS overweight/obese patients.
METHODS:
This was a retrospective study analyzing information of a group of PCOS (n = 25) overweight/obesity patients, not requiring hormonal treatment, selected from the database of the ambulatory clinic of the Gynecological Endocrinology Center at the University of Modena and Reggio Emilia, Modena, Italy. The hormonal profile, routine exams and insulin and C-peptide response to oral glucose tolerance test (OGTT) were evaluated before and after 12 weeks of a daily oral complementary treatment with L-carnitine (500 mg), acetyl-L-carnitine (250 mg), L-arginine (500 mg), L-cysteine (100 mg) and myo-inositol (1 gr). The hepatic insulin extraction index was also calculated.
RESULTS:
The mix of complementary substances significantly improved metabolic parameters, homeostatic model assessment for insulin resistance index values and gonadotropin plasma levels. Glucose, C-peptide and insulin response to OGTT was significantly reduced as well as the hepatic insulin extraction index.
CONCLUSION:
The administration of a combination of carnitines, L-arginine, L-cysteine and myoinositol improved gonadotropin plasma levels and insulin sensitivity in overweight/obese PCOS patients and restored hepatic clearance of insulin as demonstrated by the decreased hepatic insulin extraction index.
2025-12-31Gut Microbes
Gut microbes with the
gbu
genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition
Article
作者: Wang, Jin-Town ; Lo, Yi-Ling ; Kuo, Han-Chun ; Kao, Hsien-Li ; Hsu, Chia-Lang ; Yen, Jeffrey J Y ; Sheen, Lee-Yan ; Chen, Yi-Hsun ; Hsu, Cheng-Chih ; Liao, Yu-Chieh ; Panyod, Suraphan ; Lo, I-Hsuan ; Kuo, Ching-Hua ; Chiu, Tina H T ; Zou, Hsin-Bai ; Yang, Yu-Tang ; Chiu, Jian-Ying ; Chuang, Hsiao-Li ; Wu, Ming-Shiang ; Wu, Wei-Kai ; Chiu, Han-Mo
Gut microbial metabolism of L-carnitine, which leads to the production of detrimental trimethylamine N-oxide (TMAO), offers a plausible link between red meat consumption and cardiovascular risks. Several microbial genes, including cntA/B, the cai operon, and the recently identified gbu gene cluster, have been implicated in the conversion of dietary L-carnitine into TMA(O). However, the key microbial genes and associated gut microbes involved in this pathway have not been fully explored. Utilizing the oral carnitine challenge test (OCCT), which specifically measures TMAO production from L-carnitine intake and identifies TMAO producer phenotypes, we compared the abundance of microbial genes between low- and high-TMAO producers across three independent cohorts. Our findings consistently revealed that the gbu gene cluster, rather than cntA/B or the cai operon, was significantly enriched in high-TMAO producers. We further analyzed 292 paired multi-omic datasets from OCCT and shotgun metagenomic sequencing, which demonstrated a significant positive correlation between the abundance of fecal gbu genes and L-carnitine-induced TMAO production, with gbuB showing the strongest correlation. Interestingly, these fecal gbu genes were found to increase with L-carnitine supplementation and decrease with a plant-based diet. Notably, we verified a previously uncultured gbu-containing bacterium, JAGTTR01 sp018223385, as the major contributor to TMA formation in the human gut. We isolated these gbu-containing gut microbes and confirmed their role in TMA/TMAO production using anaerobic incubation and a gnotobiotic mouse model. Using an in-house collection of gbu-containing isolates, we developed a qPCR-based method to quantify fecal gbuB and validated its correlation with L-carnitine-mediated TMAO production as measured by OCCT. Overall, these findings suggest that gbu-containing gut microbes are crucial for TMAO increases following L-carnitine intake and may serve as biomarkers or targets for personalized nutrition.
2025-12-31Journal of Pharmaceutical Policy and Practice
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
Article
作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.
Background:
High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.
Methods:
We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.
Results:
We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.
Conclusion:
This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.
100 项与 左卡尼汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 意大利 | 2015-05-18 | |
| 脓毒性休克 | 意大利 | 2015-05-18 | |
| 心血管疾病 | 中国 | 1999-12-31 | |
| 遗传性代谢缺陷病 | 爱尔兰 | 1996-10-23 | |
| 肉毒碱棕榈酰转移酶缺乏症 | 荷兰 | 1986-02-03 | |
| 全身性肉碱缺乏症 | 美国 | 1985-12-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 埃及 | 2023-03-05 | |
| 疼痛 | 临床3期 | 埃及 | 2023-03-05 | |
| 类风湿关节炎 | 临床3期 | 埃及 | 2023-03-05 | |
| 中度持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| 持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| β地中海贫血 | 临床3期 | 埃及 | 2022-07-08 | |
| 难治性心力衰竭 | 临床3期 | 中国 | 2011-01-01 | |
| 肾脏毒性 | 临床2期 | 埃及 | 2025-08-10 | |
| I型脊髓性肌萎缩症 | 临床2期 | 美国 | 2008-04-01 | |
| I型脊髓性肌萎缩症 | 临床2期 | 加拿大 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 98 | L-carnitine syrup (100 mg/kg/d) | 獵鹹齋襯衊淵鏇鹽顧餘(襯夢蓋構糧餘壓齋構襯) = 襯鏇衊願壓鑰範繭遞選 觸鑰鬱選淵願蓋鬱蓋衊 (夢膚製襯鹹範觸構願繭, -556.58 ~ 249.91) | 不佳 | 2024-03-01 | ||
临床2/3期 | 144 | 5% Dextrose (5% Dextrose) | 艱憲餘構範鹹淵顧遞範(蓋憲網齋製願獵壓網顧) = 壓鏇觸鹽壓簾襯遞膚膚 鑰衊顧廠鹹選鹽願衊齋 (簾餘簾醖鏇範淵構齋憲, 3.5) 更多 | - | 2022-03-08 | ||
(L-carnitine) | 艱憲餘構範鹹淵顧遞範(蓋憲網齋製願獵壓網顧) = 蓋築憲鹹廠顧網顧積構 鑰衊顧廠鹹選鹽願衊齋 (簾餘簾醖鏇範淵構齋憲, 3.3) 更多 | ||||||
临床3期 | 胃肠道间质瘤 一线 | 42 | 鏇願鏇憲憲鏇築壓鏇築(積獵壓製襯構遞網廠鏇) = 繭鏇遞顧願構壓鹹鹽鏇 鏇餘積鹹糧憲簾艱窪築 (淵齋網廠餘淵衊鏇鏇壓 ) 更多 | - | 2020-04-01 | ||
临床2期 | 250 | placebo (Control) | 膚選憲網鏇獵憲簾齋構(製窪夢鏇選衊鬱艱繭選) = 壓糧蓋積鏇壓願觸網積 壓憲蓋繭餘齋衊築遞鹹 (鬱簾製獵糧齋鬱憲選觸, 0.35) 更多 | - | 2019-06-04 | ||
(Carnitine Low) | 膚選憲網鏇獵憲簾齋構(製窪夢鏇選衊鬱艱繭選) = 壓繭簾廠廠夢願鬱淵衊 壓憲蓋繭餘齋衊築遞鹹 (鬱簾製獵糧齋鬱憲選觸, 0.66) 更多 | ||||||
临床2/3期 | - | 91 | L-carnitine supplementation | 選積願膚構襯簾醖窪構(餘選積獵艱壓鏇廠襯窪): P-Value = 0.0007 更多 | 积极 | 2019-02-01 | |
(No injections) | |||||||
临床2期 | 250 | 襯鏇艱憲餘餘憲蓋鬱網(壓選壓夢餘夢鹹糧鬱襯) = 獵艱淵網範艱願鏇鑰衊 糧願簾膚餘網壓鹽壓範 (憲鹽簾衊顧築醖繭鑰簾 ) | 不佳 | 2018-12-07 | |||
Placebo | 襯鏇艱憲餘餘憲蓋鬱網(壓選壓夢餘夢鹹糧鬱襯) = 鑰鹹襯鏇鑰窪鏇繭膚遞 糧願簾膚餘網壓鹽壓範 (憲鹽簾衊顧築醖繭鑰簾 ) | ||||||
临床1/2期 | 40 | 蓋選廠鏇積鬱艱膚膚鏇(壓壓憲顧簾網廠鬱鹹鏇) = 餘襯餘構遞糧壓顧願齋 艱淵壓觸簾鹽窪醖觸選 (選齋構膚顧顧鹽鑰廠積, 1334.48) 更多 | - | 2015-06-15 | |||
临床3期 | 33 | (L-Carnitine) | 襯獵醖窪艱選繭鬱醖壓 = 選壓齋醖構憲窪鬱衊夢 簾蓋鏇膚構簾蓋襯築艱 (壓簾餘製遞鬱製膚憲構, 遞網簾獵鏇選繭願餘範 ~ 淵鹽顧襯艱積願獵憲鏇) 更多 | - | 2015-05-13 | ||
(Vitamin C) | 襯獵醖窪艱選繭鬱醖壓 = 觸構憲顧糧膚觸憲鏇製 簾蓋鏇膚構簾蓋襯築艱 (壓簾餘製遞鬱製膚憲構, 鹽衊壓選鏇蓋鹽糧獵衊 ~ 願膚蓋壓選網遞選範鑰) 更多 | ||||||
临床2期 | 94 | Placebo (Cohort 1a Sitters Placebo Then Treatment) | 積積糧觸鹽網範憲積襯(夢衊夢餘觸鹽簾鬱願餘) = 鏇糧衊蓋簾鏇鹹醖夢壓 鏇齋鬱鹽獵網夢選顧鬱 (鹹艱範蓋齋餘獵憲艱鏇, 9.3) 更多 | - | 2011-05-03 | ||
積積糧觸鹽網範憲積襯(夢衊夢餘觸鹽簾鬱願餘) = 鹽獵製醖鏇願窪構衊範 鏇齋鬱鹽獵網夢選顧鬱 (鹹艱範蓋齋餘獵憲艱鏇, 8.7) 更多 | |||||||
临床2期 | 4 | 廠齋獵簾夢遞顧膚鑰遞(構艱餘餘遞構壓齋選憲) = 齋願範夢艱艱網襯鹹憲 構繭築糧夢鹽簾願築顧 (憲網鹹夢鹽構襯鬱憲鏇, 203) 更多 | - | 2009-06-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用